Adverse Event reporting information can be found in footer

Request a Meeting


FIRMAGON® is a different class of ADT

The 2 classes of ADT used to treat hormone-dependent prostate cancer10

LHRH agonists overstimulate gonadotrophin releasing hormone (GnRH) receptors and rely on negative feedback to achieve their effect, but may cause an initial clinical flare.

FIRMAGON®, a GnRH antagonist that blocks GnRH receptors directly, enabling rapid testosterone suppression.10


Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.